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Two issues in the ﬁeld of chemically mediated
endocrine disruption (ED) are the possible
occurrence of ED effects at dose levels lower
than the no effect level defined by classical
toxicity evaluations, and how to interpret weak
chemically induced ED effects that lie within
the range of normally encountered control
variability (Ashby 2003). We have studied sev-
eral reports of low-dose ED effects over the
past 6 years, so far without being able to con-
firm any of them; these chemicals include
butylbenzylphthalate (BBP) (Ashby et al.
1997; Sharpe et al. 1995, 1998); bisphenol A
(BPA) (Ashby et al. 1999, 2003; Nagel et al.
1997; Sakaue et al. 2001; Talsness et al. 2000;
Tinwell et al. 2002a); and nonylphenol (NP)
(Colerangle and Roy 1996; Lee 1998; Odum
and Ashby 2000; Odum et al. 1999). In con-
trast, we were able to conﬁrm (Tinwell et al.
2002b) the weak uterotrophic activity of
3-(4-methylbenzylidene)camphor (4MBC)
reported by Schlumpf et al. (2001a, 2001b),
despite the inability of Bolt et al. (2001) to
conﬁrm this activity.
Recently, we encountered two instances
that may throw light on the origins of these
reproducibility problems. The first of these
was the observation of an apparent inverted-U
low-dose effect for the 5α-testosterone reduc-
tase inhibitor finasteride (FIN) in the
Hershberger antiandrogen assay, an effect we
were unable to reproduce. The second was our
inability (after publication of Tinwell et al.
2002b) to reconﬁrm our own observation of
uterotrophic activity for 4MBC. In each case,
further studies revealed that control variability
between experiments was probably at the root
of these reproducibility problems. This con-
clusion led us to reevaluate earlier ﬁndings for
BPA in the mouse uterotrophic assay (Tinwell
et al. 2000) and to analyze earlier reports of
low-dose effects for BPA (Howdeshell et al.
2003; Nagel et al. 1997; Nonneman et al.
1992; Sakaue et al. 2001) and NP (Lee 1998).
Materials and Methods
Chemicals. We obtained testosterone propi-
onate (TP) and FIN from Sigma Chemical
Company (Poole, Dorset, UK). Tocopherol-
stripped corn oil (ICN Biomedicals Inc.,
Basingstoke, Hampshire, UK) was used to sus-
pend FIN and TP by homogenization (Ashby
1987). We obtained 4MBC (CAS Registry No.
38102-62-4; Merck batch TT805785 029)
from ChemQuest (Wilmslow, Cheshire, UK)
and diethylstilbestrol (DES) from Sigma
Chemical Company. Antarelix (ANT) was a
gift from Europeptides (Argenteuil, France).
We used arachis oil (AO; Sigma Chemical
Company) as the vehicle for 4MBC (homoge-
nized as described previously; Tinwell et al.
2002b), DES, and ANT. All chemicals were
stored at room temperature except ANT,
which was stored at 4°C. All preparations were
shaken vigorously just before and during dos-
ing. All experiments were conducted according
to U.K. Home Ofﬁce guidelines as described
in the appropriate Home Office license for
animal use.
Hershberger assays. Animals. Male
Alpk:APfSD rats (animal breeding unit at
AstraZeneca Pharmaceuticals, Macclesfield,
Cheshire, UK) were castrated at 6 weeks of
age via midline incision followed by 8 days of
recovery. In each study, the animals were ran-
domized into groups of six rats of approxi-
mately the same initial mean body weight
and range. They were group housed at a max-
imum of six per cage in solid-bottomed
polypropylene cages containing sawdust
(Wood Treatments Ltd., Macclesfield,
Cheshire, UK) and shredded paper as bed-
ding. Fun tubes and houses were provided as
environmental enrichment. All animals were
given RM1 diet (Special Diet Services Ltd.,
Witham, Essex, UK) and water ad libitum for
the duration of the experiment.
Study design. The experimental method
has been described previously (Ashby and
Lefevre 2000). Rats were given 10 consecu-
tive daily treatments consisting of a subcuta-
neous (sc) injection of either the corn oil
vehicle or TP (0.4 mg/kg) and an oral dose of
either vehicle or the relevant dose of FIN. We
used 5 mL/kg and 2 mL/kg dosing volumes
for oral and subcutaneous administrations,
respectively.
The animals were killed 24 hr after the
last treatment by an overdose of halothane
(Concord Pharmaceuticals Ltd., Essex, UK).
The following tissues were removed and
weighed at necropsy: liver and combined kid-
neys (to 1 mg), Cowper’s glands, levator
ani/bulbo cavernosus muscles (LA/BC), semi-
nal vesicles (with coagulating gland), ventral
prostate, glans penis, and combined adrenal
glands (all to 0.1 mg). Changes in tissue
weights were evaluated for statistical signifi-
cance using analysis of variance (ANOVA)
and analyses of covariance (ANCOVA) with
ﬁnal body weight.
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Natural Variability and the Inﬂuence of Concurrent Control Values on the
Detection and Interpretation of Low-Dose or Weak Endocrine Toxicities
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While defining the no effect level for the 5α-reductase inhibitor finasteride in the Hershberger
assay, we encountered an inverted-U low-dose trophic effect on the prostate gland of the rat. Two
attempts to conﬁrm this observation were unsuccessful, and we concluded that the positive effect
initially observed was associated with normal biologic variability. During the same period we
attempted, unsuccessfully, to repeat our own observation of weak uterotrophic activity in the rat for
the sunscreen 3-(4-methylbenzylidene)camphor (4MBC). Further evaluation led us to conclude
that 4MBC is uterotrophic only when the control uterine weights are at the low end of their nor-
mally encountered range. This led us to reevaluate our earlier mouse uterotrophic assay data for
bisphenol A (BPA). Originally we had concluded that BPA gave irreproducible evidence of weak
uterotrophic activity, but upon ordering the eight experiments we had conducted, according to
decreasing control uterine weight, we conﬁrmed reproducible weak uterotrophic activity for BPA
when the control uteri were at the low end of their normal range. In this article, we describe these
observations, together with a reanalysis of the data associated with several reported instances of
weak or low-dose endocrine effects that have proven difﬁcult to conﬁrm in independent laborato-
ries. These include the activity of BPA on the CF1 mouse prostate; the activities of BPA, octyl-
phenol, and nonylphenol on the rat testis; and the effect of polycarbonate caging on control mouse
uterine weight. In all of these cases, variability among controls provides a major obstacle to data
interpretation and conﬁrmation. Our recommendations on experimental design are also presented,
with a view to ending the current impasse on the reality, or otherwise, of low-dose or weak
endocrine toxicities. Key words: 3-(4-methylbenzylidine)camphor, bisphenol A, endocrine disrup-
tion, finasteride, low dose, nonylphenol. Environ Health Perspect 112:847–853 (2004).
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The experimental methods were as described
previously (Odum et al. 2001). Female
Alpk:APfSD (Wistar derived) rats were
obtained from the barriered animal breeding
unit (AstraZeneca). These were 19–20, 20–21,
21–22, or 22–23 days of age at the beginning
of the study. The animals were housed up to a
maximum of six per cage as described for the
Hershberger assay. Each female received an sc
injection of the appropriate compound on
3 consecutive days and was killed 24 hr after
the last dose. On the basis of previously pub-
lished data, 4MBC was given at 1 g/kg
(Tinwell et al. 2002b) and ANT was given at
300 µg/kg (Odum et al. (2001); 5 µg/kg DES
was used as a positive control. We used a dos-
ing volume of 5 mL/kg body weight when ani-
mals were exposed to a single compound.
However, in studies in which the animals were
exposed to test compound and ANT, we used
a dosing volume of 2.5 mL/kg body weight.
Females were exposed to ANT 15 min before
receiving the appropriate test compound (AO,
4MBC, or DES).
Study design. 4MBC had previously been
shown to induce a signiﬁcant increase in uter-
ine weight in immature rats (Tinwell et al.
2002b). Thus, the initial experiment in the
present study was designed to repeat those
original observations. We also included addi-
tional groups of animals exposed to 4MBC
together with the gonadotropin-releasing hor-
mone (GnRH) antagonist ANT. In this exper-
iment, 4MBC failed to significantly increase
the uterine weight; however, the control uter-
ine weights were greater than usual. Therefore,
we repeated the experiment. In the ﬁnal two
experiments, we used animals of different ages
at the start of the uterotrophic assays. All ani-
mals were killed 24 hr after the last dose by an
overdose of ﬂuothane followed by cervical dis-
location. The uterus was removed, trimmed
free of fat, gently blotted, and weighed. It was
then placed in a preweighed vial, dried
overnight (24 hr) at 70°C, and reweighed. All
data were assessed for statistical significance
using a two-sided Student’s t-test. 
Results
Hershberger assays. The assays for FIN
described in this article represent a continua-
tion of previous experiments (Ashby and
Lefevre 2000; Blohm et al. 1986) and studies
conducted as part of the current Organisation
for Economic Co-operation and Development
(OECD) validation of the Hershberger assay.
The OECD studies demonstrated that a dose
of FIN as low as 200 µg/kg/day inhibited the
growth of the seminal vesicles, ventral
prostate, and glans penis of TP-treated rats
(J. Ashby, unpublished data). Subsequently,
we have shown that doses of FIN as low as
8 µg/kg/day are active in the assay (Ashby
et al. 2004), with the prostate gland being
the most sensitive tissue (Figure 1). The pre-
sent experiments were designed to determine
the no effect level for the inhibitory effect on
the growth of the prostate in TP-treated ani-
mals. In all of the experiments, a dose of
5,000 µg/kg/day FIN significantly inhibited
the growth of the seminal vesicles, ventral
prostate, Cowper’s glands, and glans penis
compared with animals administered only
TP (Table 1). In one study (experiment 1,
Table 1) growth of the LA/BC was also
signiﬁcantly inhibited.
In the first low-dose experiment (experi-
ment 1, Table 1), doses ranging from
5,000 µg/kg/day to 8 µg/kg/day FIN were all
clearly active in the assay. The lowest dose
tested (8 µg/kg/day FIN) affected all tissues
except the LA/BC and the Cowper’s glands. In
experiment 2 (Table 1), the only tissues signiﬁ-
cantly inhibited at 8 µg/kg/day FIN were the
seminal vesicles and glans penis. The glans
penis was reduced in weight at all dose levels of
FIN down to 0.1 µg/kg/day (Figure 2).
However, the ventral prostate weight was sig-
nificantly increased (p < 0.01) for the
2µ g/kg/day dose of FIN. In attempts to repeat
this inverse prostate weight dose response
(Figure 1), we conducted two further experi-
ments (experiments 3 and 4, Table 1) using a
tighter dose range of FIN around the dose that
had increased prostate weight in experiment 2.
In the first of these repeat studies (experi-
ment 3, Table 1), the only signiﬁcant weight
change observed was an increase in the weight
of the Cowper’s glands at 5 µg/kg/day FIN.
This increase is probably associated with bio-
logic variation and is probably not biologically
signiﬁcant (compare values for Cowper’s glands
weights in experiments 1–4, Table 1).
However, seemingly in support of the previous
experiment, we observed an inverted-U shaped
response for increases in prostate weight around
the 2 µg/kg/day dose of FIN, but none of the
effects were statistically signiﬁcant (Figure 1). In
experiment 4, we did not observe the same pat-
tern in the increase of the Cowper’s glands
weight seen in the experiment 3 (Table 1), and
no change in prostate weight was observed
below the 5,000 µg/kg/day positive control
dose of FIN (Figure 1). In that final experi-
ment, we observed a statistically significant
reduction in the weight of the seminal vesicles
at 5 µg/kg/day FIN. Inhibition of the growth of
the glans penis was not consistently observed in
these experiments (Figure 2).
The data sets recorded for the prostate
gland during the course of these experiments
are shown in Figure 1, both in terms of the
weight of the prostate gland relative to the con-
current control value (taken as 100%) and in
terms of absolute prostate weights.
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Figure 1. Rat prostate weights from four Hershberger assays of FIN shown as (A) a percentage of the con-
current control or as (B) absolute weights (mean ± SD) (data from Table 1).
**p < 0.01 versus relevant control. 
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FIN (µg/kg)Variability in control tissue and body
weights. We calculated a mean of each control
tissue weight and of control body weights from
the four experiments, yielding a new mean
weight value for all controls (corn oil + TP)
combined. These means, multiplied by the SD
of the mean and divided by 100, yield a per-
centage of the variation in control weights
between experiments. The control prostate
weights showed the highest variability between
experiments, as follows: prostate, 11%;
Cowper’s glands, 6%; seminal vesicles, 5%;
glans penis, 4%; LA/BC, 4%; liver, 1.8%; kid-
neys, 1.5%; body weight, 1.1%. The relatively
high variability of all of the sex accessory tissues,
compared with the liver and kidney weights
and body weight, probably relates to the fact
that the stimulatory dose of TP used in these
Hershberger assays causes submaximal growth
of the tissues, being just below the plateau-
inducing dose of TP (Ashby and Lefevre 2000).
Thus, small pharmacodynamic differences
between experiments may yield small differ-
ences in the stimulatory dose of TP experienced
by the tissues between experiments.
Uterotrophic assays. The data for the
uterotrophic studies of 4MBC are presented in
Table 2. We have previously shown 4MBC to
be reproducibly active in the immature rat
uterotrophic assay in this laboratory (Tinwell
et al. 2002b) (experiment 1, Table 2).
However, in the initial repeat study (experi-
ment 2, Table 2), 4MBC failed to induce a
signiﬁcant increase in uterine weight. In this
experiment the control uterine weights were
heavier than usual: 35.1 ± 5.9 compared with
23.3 ± 4.3 (experiment 1, Table 2; Tinwell
et al. 2002b); thus, a repeat of this study was
undertaken (experiment 3, Table 2). In exper-
iment 3, control uterine weights were within
our normal range, and 4MBC induced a
weak, although signiﬁcant (p < 0.01), increase
in uterine weight. This activity was abolished
by the GnRH inhibitor ANT, suggesting that
the uterotrophic effects were mediated cen-
trally via a temporal advance in puberty rather
than via a direct effect of 4MBC on the
uterus. Two further experiments were there-
fore performed in which we investigated the
effect of the initial age of the rat on the activ-
ity of 4MBC (experiments 4 and 5, Table 2).
Although 4MBC led to an increase in uterine
weight in experiments 4 and 5, the signifi-
cance of the response diminished with the
older animals. Thus, the response to 4MBC
was highly signiﬁcant (p < 0.01) when 19–20-
day-old animals were used; this was reduced to
p < 0.05 with 20–21-day-old animals, and the
response was not significant when the older
animals (21–22 and 22–23 days old) were
used. These effects were reproducible between
experiments 4 and 5 (Table 2).
Discussion
FIN inhibits the production of dihydrotestos-
terone from testosterone and consequently
shows activity as a male rat developmental
toxin with a lowest active dose of 10 µg/kg/day
(Bowman et al. 2003). FIN also shows repro-
ducible antiandrogenic activity in the
Hershberger assay (Hershberger et al. 1953)
at doses of ≥ 8 µg/kg (Figure 1A; Ashby et al.
2004). The present studies initially demon-
strated a statistically significant low-dose
trophic effect on the prostate gland at 2 µg/kg
(experiment 2, Figure 1A), suggesting an
androgenic, as opposed to antiandrogenic,
effect. In the first attempted repeat of this
trophic effect (experiment 3), we observed a
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Table 1. Tissue weights from castrated rats administered corn oil (oral), corn oil + TP (0.4 mg/kg sc), or corn oil + TP + FIN (oral), each for 10 consecutive days.
Experiment Treatment Body weight (mean ± SD) Tissue weight (mean ± SD)
no. (µg/kg) Initial weight (g) Final weight (g) Liver (g) Kidneys (g) Adrenals (mg) LA/BC (mg) CG (mg) SV (mg) Prostate (mg) Glans penis (mg)
1 Corn oil alone 244.5 ± 13.0 305.5 ± 23.2 13.69 ± 1.53 2.22 ± 0.11 64.2 ± 4.4 148.8 ± 18.2 5.6 ± 0.4 64.8 ± 10.9 24.8 ± 14.0 70.7 ± 6.1
TP + corn oil 247.2 ± 8.6 342.5 ± 17.1 16.37 ± 1.28 2.45 ± 0.21 52.0 ± 7.4 381.2 ± 35.6 37.7 ± 2.1 506.8 ± 35.1 168.6 ± 13.1 122.4 ± 5.7
TP + FIN 8  242.8 ± 13.9 335.2 ± 18.9 15.88 ± 1.32 2.47 ± 0.17 49.3 ± 4.2 353.1 ± 37.7 36.9 ± 3.2 405.0 ± 42.4** 114.9 ± 12.4** 110.1 ± 8.2**
TP + FIN 40 243.7 ± 13.4 335.8 ± 20.4 15.71 ± 1.22 2.34 ± 0.26 53.7 ± 9.7 348.0 ± 20.7 34.0 ± 4.6* 335.5 ± 37.0** 97.6 ± 23.2** 103.4 ± 7.6**
TP + FIN 200 246.5 ± 10.0 333.8 ± 18.8 15.34 ± 0.50 2.36 ± 0.14 54.8 ± 4.8 317.2 ± 30.9** 32.1 ± 1.3** 295.0 ± 27.8** 76.9 ± 10.1** 101.6 ± 7.2**
TP + FIN 5,000 248.8 ± 10.2 338.2 ± 11.9 15.73 ± 1.13 2.38 ± 0.20 53.5 ± 3.2 314.3 ± 51.5** 22.0 ± 3.7** 188.9 ± 25.2** 58.0 ± 8.5** 98.7 ± 8.4**
2 TP + Corn oil 264.0 ± 8.6 349.2 ± 11.1 16.63 ± 0.82 2.47 ± 0.22 53.4 ± 8.7 359.4 ± 76.5 39.4 ± 2.4 508.1 ± 71.5 143.3 ± 26.3 121.9 ± 8.9
TP + FIN 0.1 258.7 ± 7.4 350.2 ± 13.8 16.98 ± 1.12 2.43 ± 0.11 58.1 ± 8.8 366.8 ± 25.0 38.9 ± 2.7 516.7 ± 89.4 141.2 ± 24.3 112.9 ± 9.3*
TP + FIN 0.5 267.2 ± 9.2 354.0 ± 14.3 17.28 ± 0.98 2.51 ± 0.12 61.4 ± 7.9 358.7 ± 41.7 35.9 ± 3.2 479.5 ± 32.6 140.9 ±16.2 110.1 ± 6.5**
TP + FIN 2.0 261.5 ± 13.0 348.0 ± 24.9 16.82 ± 1.31 2.42 ± 0.10 55.6 ± 7.2 367.1 ± 35.9 38.6 ± 3.0 528.6 ± 66.3 178.6 ± 8.9**↑ 112.5 ± 11.5*
TP + FIN 8.0 263.0 ± 4.6 351.2 ± 8.7 17.75 ± 1.03* 2.53 ± 0.14 50.0 ± 8.3 354.9 ± 45.5 39.6 ± 4.6 423.6 ± 52.5* 129.6 ± 13.3 111.3 ± 4.6*
TP + FIN 5,000 264.0 ± 8.8 359.2 ± 14.2 17.49 ± 0.64 2.44 ± 0.08 49.9 ± 8.6 333.7 ± 12.6 23.9 ± 3.7** 215.7 ± 42.4** 60.2 ± 13.5** 99.2 ± 4.4**
3 TP + Corn oil 255.7 ± 10.6 340.5 ± 18.5 16.90 ± 1.41 2.40 ± 0.22 56.6 ± 11.1 345.3 ± 41.1 34.3 ± 3.6 466.5 ± 35.6 132.5 ± 32.9 120.8 ± 8.0
TP + FIN 0.5 256.3 ± 12.6 339.2 ± 12.8 16.44 ± 0.87 2.30 ± 0.06 56.5 ± 4.1 373.3 ± 30.6 36.8 ± 4.5 474.8 ± 36.0 153.3 ± 27.9 112.5 ± 7.1
TP + FIN 1.0 252.3 ± 8.6 334.3 ± 14.2 16.35 ± 1.35 2.44 ± 0.13 57.8 ± 2.8 333.8 ± 35.9 37.3 ± 1.2 443.9 ± 49.0 159.9 ± 31.7 110.9 ± 11.0
TP + FIN 2.0 255.2 ± 5.9 342.8 ± 18.8 17.20 ± 2.00 2.49 ± 0.09 54.4 ± 7.0 362.6 ± 29.2 36.6 ± 3.7 474.9 ± 60.6 151.6 ± 29.3 115.9 ± 8.4
TP + FIN 5.0 256.8 ± 9.1 341.0 ± 22.4 16.63 ± 1.83 2.49 ± 0.21 54.1 ± 5.4 365.0 ± 21.3 38.7 ± 3.7*↑ 457.9 ± 38.1 140.2 ± 14.0 114.4 ± 12.3
TP + FIN 5,000 251.2 ± 8.1 332.8 ± 11.7 16.10 ± 0.74 2.34 ± 0.12 53.3 ± 2.9 319.6 ± 32.9 24.6 ± 2.2** 182.2 ± 24.3** 60.8 ± 6.6** 96.6 ± 7.6**
4 TP + Corn oil 252.5 ± 10.5 343.3 ± 14.5 17.05 ± 1.06 2.48 ± 0.08 61.5 ± 7.7 365.3 ± 31.5 37.9 ± 3.4 458.1 ± 36.9 142.0 ± 21.1 112.5 ± 5.3
TP + FIN 0.5 252.7 ± 7.1 344.7 ± 6.2 17.43 ± 0.70 2.54 ± 0.11 60.5 ± 10.3 360.4 ± 48.1 41.8 ± 2.9 482.8 ± 44.9 134.1 ± 27.8 108.9 ± 5.7
TP + FIN 1.0 252.8 ± 7.2 341.5 ± 7.1 17.23 ± 0.98 2.44 ± 0.12 60.1 ± 10.9 361.9 ± 34.5 39.2 ± 6.1 432.0 ± 49.2 130.4 ± 17.7 110.2 ± 9.9
TP + FIN 2.0 250.3 ± 9.3 330.0 ± 18.9 16.27 ± 1.51 2.38 ± 0.09 58.8 ± 6.4 360.5 ± 30.4 37.8 ± 4.3 463.1 ± 45.6 128.6 ± 10.0 113.5 ± 9.2
TP + FIN 5.0 251.0 ± 10.6 336.5 ± 14.3 16.99 ± 1.16 2.40 ± 0.10 56.5 ± 9.7 376.3 ± 18.7 35.5 ± 4.0 380.7 ± 71.7* 125.5 ± 17.3 107.4 ± 10.9
TP + FIN 5,000 254.8 ± 8.9 341.7 ± 14.3 17.52 ± 0.86 2.46 ± 0.22 51.4 ± 8.2 340.0 ± 21.9 21.1 ± 4.9** 160.8 ± 23.5** 50.5 ± 9.7** 93.2 ± 6.4**
Abbreviations: CG, Cowper’s glands; SV, seminal vesicles; ↑, elevated tissue weight.
*p < 0.05 and **p < 0.01, FIN + TP versus corn oil + TP by ANOVA and ANCOVA. 
Figure 2. Absolute glans penis weights (mean ± SD) from four Hershberger assays of FIN (data from Table 1). 
*p < 0.05 and ** p < 0.01 versus control. 
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**statistically nonsigniﬁcant increase in prostate
weight at the 2-µg/kg dose, and in experiment
4 no effects were seen (Figure 1A). Because
reproducibility of an effect is the primary cri-
terion of its validity, we conclude that FIN
does not show low-dose endocrine effects. In
seeking an explanation for the initially
observed low-dose trophic effect of FIN, we
noticed that control prostate weights were the
most variable of all of the tissue weights
recorded in the Hershberger assay: 11% vari-
ance for prostate compared with values as low
as 1.1% for body weights (see “Variability in
control tissue and body weights” in “Results”).
This variability is evident in Figure 1B, which
shows absolute prostate weights for the series
of experiments with FIN. Thus, the control
prostate weight in experiment 1 is essentially
the same as the statistically increased prostate
weight recorded for the FIN group in experi-
ment 2. This variability in control prostate
weights raises the strong possibility that the
signiﬁcant effect seen for the low dose of FIN
was a chance observation occurring within the
normal interexperimental control range.
Similarly, although the variability in control
glans penis weights (4%) was lower than that
for the prostate (11%), it is probable that the
nonreproducible decreases in glans penis
weight also induced by low doses of FIN in
experiment 2 were associated with normal
biologic variability (Figure 2). The key points
from these data for FIN are that the increase
in prostate weight and the decreases in glans
penis weights induced by FIN were all within
the control range encountered for these tis-
sues in the present experiments, and the
effects induced were not reproducible.
The uterotrophic activity of 4MBC
(Table 2, Figure 3) was dependent upon the
weight of the control uteri in the relevant
experiment. There is no way to select for low
control uterine weights because there is not a
predictive correlation between initial body
weight and uterine weights observed 4 days
later (Table 2). Thus, it is a matter of chance
whether an experiment has control uteri in the
low weight range thereby giving rise to a posi-
tive response induced by 4MBC or whether
the control uteri will be in the high range in
which case 4MBC will be negative. The data
shown in Figure 3 confirm, as expected,
that the uterus grows marginally during post-
natal days (PND) 19–25, before the major
growth phase starting at puberty (around
PND 29–30). By the time the maximum
uterine weight for this prepubertal growth is
reached (~40 mg), the assay is no longer able
to detect 4MBC as uterotrophic. The fact that
the prepubertal growth of the uterus, and the
uterotrophic activity of 4MBC, is abolished by
GnRH inhibition indicates that both effects
are centrally mediated, perhaps via modula-
tion of centrally controlled release of low levels
of estradiol from the ovaries or the adrenal
glands. These data therefore indicate that
there are two mechanisms by which an agent
can induce an uterotrophic response. The ﬁrst
mechanism, as illustrated by the reference
Article | Ashby et al.
850 VOLUME 112 | NUMBER 8 | June 2004 • Environmental Health Perspectives
Table 2. Activity of 4MBC in the immature rat uterotrophic assay.
Age at start Uterine weight (mean ± SD) Body weight (mean ±SD)
Experiment no. of dosing (days)  Compound Dose (per kg) Blotted (mg) Dry (mg) Initial (g) Terminal (g)
1 (Tinwell et al. 2002b) AO 5 mL 23.3 ± 4.3 4.9 ± 0.8 46.9 ± 2.6 56.4 ± 3.2
4MBC 500 mg 31.1 ± 4.6** 6.0 ± 0.7** 47.3 ± 3.6 56.9 ± 5.2
4MBC 1,000 mg  29.4 ± 3.5** 5.6 ± 0.7** 46.4 ± 2.7 56.5 ± 4.1
DES 5 µg 123.6 ± 8.2** 20.9 ± 1.7** 46.1 ± 5.1 56.4 ± 5.3
2 19–20 AO 5 mL 35.1 ± 5.9 6.6 ± 0.8 46.0 ± 1.7 56.4 ± 2.3
4MBC 1,000 mg 35.1 ± 4.4 6.3 ± 0.5 46.3 ± 2.4 57.6 ± 4.4
DES 5 µg 115.5 ± 3.3** 20.0 ± 0.3* 46.2 ± 2.6 56.2 ± 2.9
ANT 300 µg 21.9 ± 4.0 4.4 ± 0.7 45.1 ± 3.2 57.2 ± 4.2
4MBC/ANT 1 g/300 µg 20.0 ± 2.2 4.3 ± 0.5 43.8 ± 3.0 57.4 ± 3.7
DES/ANT 5 µg/300 µg 125.1 ± 5.1** 19.8 ± 2.5** 46.6 ± 1.7 57.7 ± 2.2
3 19–20 AO 5 mL 20.0 ± 1.9 3.8 ± 0.6 38.5 ± 2.6 48.1 ± 2.7
4MBC 1,000 mg 26.7 ± 2.8** 4.2 ± 1.3 39.4 ± 2.1 49.3 ± 2.0
DES 5 µg 99.2 ± 6.2** 16.9 ± 1.3** 39.5 ± 1.5 51.2 ± 3.7
ANT 300 µg 16.2 ± 0.9 3.4 ± 0.3 40.0 ± 2.6 48.8 ± 3.5
4MBC/ANT 1 g/300 µg 16.8 ± 0.8 3.3 ± 0.4 40.7 ± 2.6 48.9 ± 4.1
DES/ANT 5 µg/300 µg 113.7 ± 10.9** 19.0 ± 2.4** 40.7 ±2.6 50.8 ± 3.2
4 19–20 AO 5 mL 23.7 ± 3.8 4.8 ± 0.8 43.8 ± 4.3 53.9 ± 5.1
4MBC 1,000 mg 32.1 ± 2.7** 5.8 ± 0.5** 43.2 ± 3.3 53.1 ± 4.5
DES 5 µg 108.9 ± 15.6** 19.0 ± 2.5** 42.7 ± 5.2 51.4 ± 6.1
20–21 AO 5 mL 28.0 ± 4.1 5.3 ± 0.6 49.2 ± 3.1 60.9 ± 4.0
4MBC 1,000 mg 33.1 ± 3.8* 6.3 ± 0.6 48.6 ± 2.6 60.6 ± 5.0
21–22 AO 5 mL 33.5 ± 9.8 6.3 ± 1.6 54.9 ± 5.2 65.5 ± 4.7
4MBC 1,000 mg 38.2 ± 6.0 7.1 ± 1.0 53.3 ± 4.3 66.0 ± 4.9
5 19–20 AO 5 mL 23.0 ± 1.5 4.6 ± 0.4 41.8 ± 1.4 52.1 ± 2.0
4MBC 1,000 mg 29.1 ± 4.8** 5.4 ± 0.8** 41.3 ± 2.4 50.6 ± 3.6
DES 5 µg 111.8 ± 11.5** 19.1 ± 1.7** 40.8 ± 2.4 51.7 ± 3.9
20–21 AO 5 mL 22.5 ± 3.2 4.5 ± 0.7 42.0 ± 3.2 51.1 ± 4.7
4MBC 1,000 mg 26.8 ± 3.5* 5.0 ± 0.6 42.3 ± 3.6 51.9 ± 4.0
DES 5 µg 109.9 ± 4.3** 18.1 ± 1.0** 42.7 ± 5.5 53.6 ± 6.9
21–22 AO 5 mL 26.5 ± 3.2 5.2 ± 0.5 49.6 ± 2.5 62.4 ± 3.5
4MBC 1,000 mg 28.9 ± 4.2 6.8 ± 3.5 47.9 ± 2.6 60.5 ± 3.6
DES 5 µg 121.9 ± 28.5** 20.1 ± 2.3** 50.1 ± 1.4 62.7 ± 3.4
22–23 AO 5 mL 29.8 ± 4.1 5.7 ± 0.8 49.1 ± 2.8 62.2 ± 3.1
4MBC 1,000 mg 33.4 ± 6.3 6.5 ± 1.0 49.6 ± 2.9 61.4 ± 4.0
DES 5 µg 108.6 ± 14.4** 19.4 ± 1.9** 52.1 ± 1.9 64.3 ± 3.8
All compounds were given by sc injection.
*p < 0.05, and **p < 0.01 by two-sided Student’s t-test.
Figure 3. Activity (mean ± SD) of 4MBC (1,000 mg/kg
sc) in the immature rat uterotrophic assay using
animals of different ages at the start of dosing. 
*p < 0.05; **p < 0.01.
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4MBCestrogen DES, involves direct action of the
estrogen on the uterus leading to maximal
growth of the tissue (from 20 to > 100 mg;
Table 2). This mechanism, as expected, is not
inﬂuenced by coadministration of the GnRH
inhibitor ANT. The second mechanism, as
illustrated by 4MBC, involves the test agent
inﬂuencing the centrally mediated stimulation
of prepubertal growth of the uterus. This
activity is blocked by GnRH inhibition, and
the magnitude of the uterotrophic effect is
limited to the maximum control uterine
weight that can be encountered in prepubertal
animals (~40 mg).
The fact that the activity of 4MBC in the
uterotrophic assays was dependent upon the
concurrent control uterine weight led us to
reevaluate our earlier data for BPA in the
mouse uterotrophic assay (Tinwell et al. 2000)
in which eight uterotrophic assays were
described for the BPA dose range of 0.02 µg/kg
to 300 mg/kg. Although we found some evi-
dence of weak uterotrophic activity at some
doses, none of the effects was consistently
reproducible. The clearest example of this was
for the 200-mg/kg dose of BPA, which gave
four weak positive responses and four negative
responses (Figure 4A). When those data are
reordered from chronological order into the
order of descending control uterine weights
(Figure 4B), the results become consistent with
the effects seen for 4MBC. Thus, the positive
BPA results were weak and only became signif-
icant when the control uterine weights were
low. Further, the magnitude of the effects
induced by BPA remained constant: the
decreasing control values created the statisti-
cally signiﬁcant effects for BPA. 
These data for FIN, 4MBC, and BPA
indicate that concurrent control values and
interexperimental variation in control levels
can influence the interpretation of weak
endocrine toxicities and thereby affect the
qualitative outcome of bioassays. This conclu-
sion is possibly relevant to several other
instances of low-dose or weak endocrine
effects that have proven resistant to indepen-
dent conﬁrmation. For example, Sharpe et al.
(1995) reported that octylphenol (OP) and
BBP were able to reduce rat testes weights.
We were unable to confirm those effects for
BBP (Ashby et al. 1997), and this led Sharpe
et al. to repeat their evaluation of OP (Sharpe
et al. 1998). In that repeat study, the control
testes weights had fallen and OP was no
longer active (Sharpe et al. 1998; Figure 5).
Uncertain of the origins of these effects, these
researchers ran a further control group and
recorded control testes weights similar to their
original 1995 study (Figure 5; Sharpe et al.
1998). They were unable to account for this
variability in control testes weights, and the
activity of BBP and OP in the assay remains
unconﬁrmed. A similar situation exists for the
effects of NP on the rat prostate gland (Lee
1998). Lee described a study in which NP
reduced prostate weight and in which access to
ﬁve identical control groups was possible. In
the ﬁrst four of these, control prostate weights
were approximately 60 mg/100 g body
weight, but in the fifth study this value was
significantly lower (~40 mg/100 g body
weight; Figure 6). Lee (1998) did not com-
ment on this unexpected and statistically sig-
nificant change in control prostate weight,
which itself led to the conclusion that NP was
uniquely inactive in that fifth experiment
(Figure 6). We were subsequently unable to
show any effects for NP (Odum and Ashby
2000) when tested under the conditions
described by Lee (1998), and the control
prostate weights were similar to the ﬁrst four
studies reported by Lee (1998).
A further example of how the variability
of control prostate weights can inﬂuence the
interpretation and conﬁrmation of chemically
induced effects is illustrated by the activity of
BPA on the CF1 mouse prostate gland
(Figure 7). Nonneman et al. (1992) described
the effect of intrauterine position on the sub-
sequent weight of the prostate gland of CF1
mice. Subsequently, Nagel et al. (1997), from
the same laboratory, reported the ability of
BPA to increase the weight of the mouse
prostate gland, with the implication that the
estrogenic activity of BPA had simulated the
presence of female fetuses being next to male
fetuses in utero. Cagen et al. (1999) and
Ashby et al. (1999) were unable to confirm
those effects of BPA, despite the fact that
Cagen et al. (1999) recorded control prostate
weights as low as those of Nagel et al. (1997).
Article | Control variability and low-dose ED toxicity
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Figure 4. Activity (mean ± SD) of BPA (200 mg/kg sc)
and controls in the immature mouse uterotrophic
assay ordered by (A) experiment number and
(B) decreasing control blotted uterine weight. The
blue bar in (A) indicates the range of BPA values.
Data from Tinwell et al. (2000). 
*p < 0.05; **p < 0.01. 
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Figure 5. Testis weight (mean ± SD) from 90- to
95-day-old control rats and those exposed to
1,000 µg/L OP either in utero or during lactation. The
control testes weights were reduced in the second
study compared to the original control data. An
additional control group was assessed in the repeat
(1998) study. These weights were similar to the
original 1995 data. The authors were unable to
account for these differences. 
Figure 6. Rat prostate weight (mean ± SD) from ﬁve
groups of controls reported by Lee (1998) and
repeat data from Odum and Ashby (2000). All of
Lee’s study groups (study number shown within
bar) had similar mean body weights at termination
on postnatal day (PND) 31. Lee (1998) observed
positive effects for NP in study 4 (8 mg/kg NP on
PND 6–24) but not in study 5 (8 mg/kg NP on PND
13–30); no account was given of the difference in
control prostate weights in the fifth experiment
compared with those reported in studies 1–4. In the
repeat studies of Odum and Ashby (2000), rats
were treated with 8 mg/kg NP on PND 6–24. 
*Weight significantly reduced compared to concurrent
control.
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Figure 7. Absolute weight (mean ± SD) of the
prostate from control and BPA-treated CF1 mice.
Abbreviations: 0M, male fetus positioned between
two females; 2M, male fetus positioned between
two males; IUP, intrauterine position. Group sizes
are shown above each bar. Animals were killed at 6
months of age, except for those reported by Cagen
et al. (1999), which were killed at 3 months of age.
*Statistically signiﬁcantly increased. **Signiﬁcantly differ-
ent (p < 0.01) from the 0M mice reported by Nonneman et al.
(1992). 
80
60
40
20
0
A
b
s
o
l
u
t
e
 
c
o
n
t
r
o
l
p
r
o
s
t
a
t
e
 
w
e
i
g
h
t
 
(
m
g
)
Nonneman
et al. (1992)
*
Nagel
et al. (1997)
Cagen
et al. (1999)
Ashby
et al. (1999)
* 7
7 7 7
44 22 18
52 36 29
0M 2M
11
IUP
unknown
IUP effect
Control
2 µg/kg BPA
20 µg/kg BPA
**Within the present context, the most interest-
ing aspect of the combined data shown in
Figure 7 is the variability of the control
prostate weights between laboratories and,
most particularly, within the laboratory of
Nonneman and Nagel. Again, the most inter-
esting questions are what factors inﬂuence the
unexplained variations in control prostate
weights, within and between laboratories, and
how these variations inﬂuence interpretation
of the effects seen for BPA.
A further example of the importance of
control variability is illustrated by the reports
of weak effects induced by BPA on rat testes
(Sakaue et al. 2001; Talsness et al. 2000). We
were unable to confirm the studies of either
Sakaue et al. (Tinwell et al. 2002) or Talsness
et al. (Ashby et al. 2003) after extensive stud-
ies. The results reported by Sakaue et al.
(2001) and related results from the same labo-
ratory (Ohsako et al. 2001; Sakaue et al.
1999) enable reference to four sets of control
observations for rat daily sperm production
(DSP) (Figure 8). The most marked reduction
in DSP induced by BPA in the two experi-
ments was reported by Sakaue et al. (2001)
(Figure 8). However, neither of these effects
was significantly different from the control
DSP value reported in the same year by
Ohsako et al. (2001; bar 2, Figure 8). This
therefore provides a further instance of unac-
counted control variability enveloping chemi-
cally induced effects from another study
conducted in the same laboratory. In four
independent repeat studies (Ashby et al.
2003), we found that test and control DSP
values were not significantly different from
each other and were similar to the BPA values
reported by Sakaue et al. (2001) (Figure 8).
We also have established that diet was not the
cause of the different assay outcomes (Ashby
et al. 2003; Odum et al. 2001).
The remaining question posed by the low-
dose studies on FIN is how to interpret effects
that show a nonsignificant change, as illus-
trated by the nonsignificant increase in
prostate weight seen for FIN (experiment 2,
Figure 1). If the statistical methods used are
appropriate, the absence of signiﬁcance should
indicate the absence of a chemically induced
effect. An example of this problem is provided
by Howdeshell et al. (2003), who discussed in
detail a nonsignificant increase (p = 0.31) in
uterine weight for CF1 mice housed in worn
polycarbonate cages equipped with worn poly-
carbonate drinking bottles (Figure 9).
Howdeshell et al. (2003) associated this effect
with the BPA (~300 ng/mL) that was reported
to leach from the cages during the course of
the experiment, but it may equally have been
related to the heavier body weights of the test
animals at the start of the experiment
(p = 0.17). The group sizes in that study were
large (57/group), but this represented the
pooling of three replicate experiments. It
would have been useful to know the results of
those three individual experiments to evaluate
whether the nonsigniﬁcant increase in uterine
weight was reproducible between replicates,
especially given the problems we encountered
(Tinwell et al. 2000) when evaluating the
uterotrophic activity of BPA in mice. 
Some endocrine-mediated toxicities are
highly speciﬁc to the conditions of the test, as
exemplified by the specificity of the effects
induced by BPA in the vagina of F344 rats but
not Sprague-Dawley rats (Long et al. 2000)
and by the resistance of C57 mice, as opposed
to CD1 mice, to the reproductive tract devel-
opmental effects of neonatal DES exposure
(Couse et al. 2001). Such clear-cut specifici-
ties, usually deﬁned in the same laboratory, are
distinct from the several recent failures to con-
ﬁrm endocrine toxicities between laboratories
when using ostensibly the same test protocol.
We suggest that the latter instances can only
be resolved, and avoided in future, if the fol-
lowing actions are taken: 
• For the end points being studied, it is useful
to have a historical database with which to
compare current assay performance and test
results. Inclusion of this database into publi-
cations would aid resolution of the prob-
lems described herein.
• Most laboratories experience variability in
the end points they measure. Understanding
the origin of these variations is a necessary
precursor to concluding weak endocrine
activity for test agents.
• When low-dose or weak endocrine effects
are indicated, it is important to conﬁrm the
observations before publication.
• Unadjusted data from separate experiments
should be shown, as opposed to pooled and
adjusted data. Adjusted data are subsidiary
to the original data.
•A   distinction should be drawn between effects
that lie within recent historical control levels
and those that exceed those levels. Different
mechanisms may operate in these two situa-
tions, leading to different approaches to data
extrapolation.
• Use of appropriate statistical methods
enables objective qualitative judgments to be
made. Subjective discussion of statistically
nonsigniﬁcant effects should be avoided.
REFERENCES
Ashby J. 1987. The efﬁcient preparation of corn oil suspensions.
Mutat Res 187:45. 
Ashby J. 2003. Endocrine disruption occurring at doses lower
than those predicted by classical chemical toxicity evalu-
ations: the case of bisphenol-A (BPA). Pure Appl Chem
75:2167–2180.
Ashby J, Lefevre PA. 2000. Preliminary evaluation of the major
protocol variables for the Hershberger castrated male rat
assay for the detection of androgens, antiandrogens, and
metabolic modulators. Regul Toxicol Pharmacol 31:92–105.
Ashby J, Lefevre PA, Tinwell H, Odum J, Owens W. 2004.
Testosterone-stimulated weanlings as an alternative to
castrated male rats in the Hershberger anti-androgen
assay. Regul Toxicol Pharmacol 39:229–238. 
Ashby J, Tinwell H, Haseman J. 1999. Lack of effects for low
dose levels of bisphenol A and diethylstilbestrol on the
prostate gland of CF1 mice exposed in utero. Regul Toxicol
Pharmacol 30:156–166.
Ashby J, Tinwell H, Lefevre PA, Joiner R, Haseman J. 2003. The
effect on sperm production in adult Sprague-Dawley rats
exposed by gavage to bisphenol A between postnatal
days 91–97. Toxicol Sci 74:129–138.
Ashby J, Tinwell H, Lefevre PA, Odum J, Paton D, Millward SW,
et al. 1997. Normal sexual development of rats exposed to
butyl benzyl phthalate from conception to weaning. Regul
Toxicol Pharmacol 26:102–118.
Blohm TR, Laughlin ME, Benson HD, Johnston JO, Wright CL,
Schatzman GL, et al. 1986. Pharmacological induction of
5alpha-reductase deficiency in the rat: separation of
testosterone-mediated and 5alpha-dihydrotestosterone-
mediated effects. Endocrinology 119:959–966.
Bolt HM, Guhe C, Degen GH. 2001. Comments on “In vitro and
in vivo estrogenicity of UV screens” [Letter]. Environ
Health Perspect 109:A358–A359.
Bowman CJ, Barlow NJ, Turner KJ, Wallace DG, Foster PMD.
Article | Ashby et al.
852 VOLUME 112 | NUMBER 8 | June 2004 • Environmental Health Perspectives
Figure 8. Comparison of control DSP (mean ± SD)
reported from the same laboratory [Ohsako et al.
(2001) and Sakaue et al. (1999, 2001)] and a different
laboratory (Ashby et al. 2003) with the greatest
effect induced by BPA (Sakaue et al. 2001). A range
of BPA doses was used in these experiments, and
only the dose that induced the greatest effect in
each experiment is shown: 20 µg/kg (Sakaue et al.
1999); 200 µg/kg (Sakaue et al. 2001); 200 mg/kg
(Ashby et al. 2003). The effect of BPA is not signiﬁ-
cantly different from the control reported by Ohsako
et al. (2001; bar 2: one- or two-sided Student’s t-test).
Sakaue et al. (1999) and Ohsako et al. (2001) used
Holtzman rats, and Sakaue et al. (2001) and Ashby
et al. (2003) used Sprague-Dawley rats. However,
the identical control DSP values for Holtzman rats
(Sakaue et al. 1999, bar 1) and Sprague-Dawley rats
(Sakaue et al. 2001; bar 3) indicate that rat strain is
not a key variable on control DSP values and that,
consequently, it is possible to compare data across
strains and experiments for that laboratory. 
*Reported by Sakaue et al. (2001) as statistically different
from the concurrent control (bars 3 and 4).
80
60
40
20
0
D
S
P
 
×
 
1
0
6
Sakaue
et al. (1999)
*
Control
BPA
Ohsako
et al. (2001)
Sakaue
et al. (2001)
Ashby
et al. (2003)
*
12 3 4 5 6 7 8
Figure 9. Mean (± SD) uterine weights for mice
maintained under different housing conditions
(Howdeshell et al. 2003). Abbreviations: NS, not
significant; PC, polycarbonate plastic; PP,
polypropylene plastic. Values are based on an
average of three females from six litters in three
replicate experiments; n = 57 for each group. Data
from individual experiments are not shown. 
30
20
10
0
A
b
s
o
l
u
t
e
 
b
l
o
t
t
e
d
 
u
t
e
r
i
n
e
w
e
i
g
h
t
 
(
m
g
)
PP cages/
glass bottles
PC cages/
PC bottles
NS2003. Effects of in utero exposure to ﬁnasteride on andro-
gen-dependent reproductive development in the male rat.
Toxicol Sci 74:393–406.
Cagen SZ, Waechter JM Jr, Dimond SS, Breslin WJ, Butala JH,
Jekat FW, et al. 1999. Normal reproductive organ develop-
ment in CF-1 mice following prenatal exposure to bisphenol
A. Toxicol Sci 50:36–44.
Colerangle JB, Roy D. 1996. Exposure of environmental estro-
genic compound nonylphenol to Noble rats alters cell-cycle
kinetics in the mammary gland. Endocrine 4:115–122.
Couse JF, Dixon D, Yates M, Moore AB, Ma L, Maas R, et al. 2001.
Estrogen receptor-alpha knockout mice exhibit resistance to
the developmental effects of neonatal diethylstilbestrol
exposure on the female reproductive tract. Dev Biol
283:224–238.
Hershberger LG, Shipley EG, Meyer RK. 1953. Myotrophic activ-
ity of 19-nortestosterone and other steroids determined by
the modiﬁed levator ani muscle method. Proc Soc Exp Biol
Med 83:175–180.
Howdeshell KL, Peterman PH, Judy BM, Taylor JA, Orazio CE,
Ruhlen RL, et al. 2003. Bisphenol A is released from used
polycarbonate animal cages into water at room tempera-
ture. Environ Health Perspect 111:1180–1187.
Lee PC. 1998. Disruption of male rat reproductive tract develop-
ment by administration of the xenoestrogen, nonylphenol,
to male newborn rats. Endocrine 9:105–111.
Long X, Steinmetz R, Ben-Jonathan N, Caperell-Grant A,
Young PCM, Nephew KP, et al. 2000. Strain differences in
vaginal responses to the xenoestrogen bisphenol A.
Environ Health Perspect 108:243–247.
Nagel SC, vom Saal FS, Thayer KA, Dhar MG, Boechler M,
Welshons WV. 1997. Relative binding afﬁnity-serum modiﬁed
access (RBA-SMA) assay predicts the relative in vivo bio-
activity of the xenoestrogens bisphenol A and octylphenol.
Environ Health Perspect 105:70–76.
Nonneman DJ, Ganjam VK, Welshons WV, vom Saal FS. 1992.
Intrauterine position on steroid metabolism and steroid
receptors of reproductive organs in male mice. Biol Reprod
45:723–729.
Odum J, Ashby J. 2000. Neonatal exposure of male rats to
nonylphenol has no effect on the reproductive tract.
Toxicol Sci 56:400–404.
Odum J, Pyrah IT, Foster JR, Van Miller JP, Joiner RJ, Ashby J.
1999. Comparative activities of p-nonylphenol and diethyl-
stilbestrol in Noble rat mammary gland and uterotrophic
assays. Regul Toxicol Pharmacol 29:184–195.
Odum J, Tinwell H, Jones K, Van Miller JP, Joiner RL, Tobin G,
et al. 2001. Effect of rodent diets on the sexual develop-
ment of the rat. Toxicol Sci 61:115–127.
Ohsako S, Miyabara Y, Nishimura N, Kurosawa S, Sakaue M,
Ishimura R, et al. 2001. Maternal exposure to a low dose of
2,3,7,8-tetrachlorodibennzo-p-dioxin (TCDD) suppressed
the development of reproductive organs of male rats: dose
dependent increase of mRNA levels of 5α-reductase type
2 in contrast to decrease of androgen receptor in pubertal
ventral prostate. Toxicol Sci 60:132–143. 
Sakaue M, Ohsako S, Ishimura R, Kurosawa S, Kurohmaru M,
Hayashi Y, et al. 1999. Preliminary BPA experiment. In:
127th Annual Meeting of the Japanese Society of
Veterinary Science, 2–4 April, Fujisawa, Japan, 47. 
Sakaue M, Ohsako S, Ishimura R, Kurosawa S, Kurohmaru J,
Hayashi Y, et al. 2001. Bisphenol A affects spermatogenesis
in the adult rat even at a low dose. J Occup Health
43:185–190. 
Schlumpf M, Berger L, Cotton B, Conscience-Egli M, Durrer S,
Fleischmann I, et al. 2001a. Estrogen active UV screens.
SOFW J 127:10–18.
Schlumpf M, Cotton B, Conscience M, Haller V, Steinmann B,
Lichtensteiger W. 2001b. In vitro and in vivo estrogenicity
of UV screens. Environ Health Perspect 109:239–244.
Sharpe RM, Fisher JS, Millar MM, Jobling S, Sumpter JP. 1995.
Gestational and lactational exposure of rats to xeno-
estrogens results in reduced testicular size and sperm
production. Environ Health Perspect 103:1136–1143.
Sharpe RM, Turner KJ, Sumpter JP. 1998. Endocrine disruptors
and testis development [Letter]. Environ Health Perspect
106:A220–A221.
Talsness C, Fialkowski O, Gericke C, Merker H-J, Chahoud I.
2000. The effects of low and high doses of bisphenol A on
the reproductive system of female and male rat offspring.
Congenital Anom 40:S94–S107.
Tinwell H, Haseman J, Lefevre PA, Wallis N, Ashby J. 2002a.
Normal sexual development of two strains of rat exposed in
utero to low doses of bisphenol A. Toxicol Sci 68:339–348.
Tinwell H, Joiner R, Pate I, Soames A, Foster J, Ashby J. 2000.
Uterotrophic activity of bisphenol A in the immature
mouse. Regul Toxicol Pharmacol 32:118–126.
Tinwell H, Lefevre PA, Moffat GJ, Burns A, Odum J, Spurway TD,
et al. 2002b. Confirmation of uterotrophic activity of
3-(4-methylbenzylidine)camphor in the immature rat.
Environ Health Perspect 110:533–536.
Article | Control variability and low-dose ED toxicity
Environmental Health Perspectives • VOLUME 112 | NUMBER 8 | June 2004 853